Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Wire Texas.
Press releases published on August 14, 2025
Boral Agency Earns 2025 Spot on Largest Houston-Area Hispanic-Owned Businesses List for the Second Time
EIN Presswire
·
August 14, 2025
Boral Agency earns 2025 Largest Houston-Area Hispanic-Owned Businesses honor for 2nd time, leading with bold, culturally intelligent marketing. HOUSTON, TX, UNITED STATES, August 14, 2025 /EINPresswire.com/ -- Boral Agency, a bold, multicultural, and …
AppleMD Expands Care to Include Hormone Therapy and Guided Weight Management Services
EIN Presswire
·
August 14, 2025
MISSOURI CITY, TX, UNITED STATES, August 14, 2025 /EINPresswire.com/ -- AppleMD Medical Services, led by board-certified family physician Dr. Anna Cecilia Tenorio, announces the addition of BioTE® bioidentical hormone therapy and medically guided weight …
Montage Gold Reports Fatal Accident at Its Koné Project in Côte d’Ivoire
GlobeNewswire
·
August 14, 2025
ABIDJAN, Côte d’Ivoire, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Montage Gold Corp. (“Montage” or the “Company”) (TSX: MAU, OTCQX: MAUTF) is saddened to report that a Montage colleague passed away yesterday as a result of injuries sustained in an incident that …
COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update
GlobeNewswire
·
August 14, 2025
COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company’s listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “ …
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026
GlobeNewswire
·
August 14, 2025
Submitted two additional U.S. government funding proposals during the quarter, bringing the total proposals to US$137 million Accepted as a new member of U.S. Medical CBRN Defense Consortium, strengthening government and biodefense partnerships HALIFAX, …
Regional Health Properties, Inc. and SunLink Health Systems, Inc. Complete Merger
GlobeNewswire
·
August 14, 2025
Atlanta, GA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCQB: RHEP) (OTCQB: RHEPA) today announced the completion of the merger of SunLink Health Systems, Inc. (“SunLink”) with and into Regional, with Regional …
Teladoc Health Acquires Telecare, Expanding Access to Specialist and Allied Health Care for Australians in Public and Private Health
GlobeNewswire
·
August 14, 2025
MELBOURNE, Australia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced it has acquired Telecare, an innovative, Australian tech-enabled provider of specialist and allied health care via …
Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025
GlobeNewswire
·
August 14, 2025
AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis …
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
GlobeNewswire
·
August 14, 2025
BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, …
Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
August 14, 2025
PEMGARDA® (pemivibart) net product revenue of $11.8 million reported for Q2 2025, representing 413% growth year-over-year Invivyd’s target of near-term profitability (1H 2025) was not met but remains possible with the upcoming respiratory virus season …
Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19
GlobeNewswire
·
August 14, 2025
Alignment follows Type C meeting for VYD2311 as previously disclosed BLA pathway for VYD2311 to be supported by a single, Phase 2/3 randomized, double-blind, placebo-controlled trial with a primary endpoint of reduction in symptomatic COVID-19, resembling …
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
GlobeNewswire
·
August 14, 2025
FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia Evaluation of strategic alternatives BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a …
Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2025 Financial Results and Business Highlights
GlobeNewswire
·
August 14, 2025
-- Arcadia revenues increase 11% year over year driven by 24% growth in Zola® -- -- Arcadia receives 2.7 million shares of stock in ABVE -- -- Arcadia eliminates $1M in liabilities -- DALLAS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® ( …
Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
August 14, 2025
– Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms in open label extension (OLE) 1-year trial– – Successful completion of two large randomized double-blind …
Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results
GlobeNewswire
·
August 14, 2025
Updated data from ongoing open-label Phase 1b trial demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m2 post-transplant for patients on tegoprubart Company on track to report topline results from Phase 2 BESTOW trial in kidney …
Milestone Scientific Achieves 25% Increase in Revenue for the Second Quarter of 2025
GlobeNewswire
·
August 14, 2025
ROSELAND, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial …
Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
August 14, 2025
Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right (CVR), plus a 2.5% royalty on future net sales of …
Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 14, 2025
Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bolt …
GT Biopharma Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 14, 2025
GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2’s formal safety review, it has advanced into Cohort 3 and initiated dosing of the fifth patient in the study; …
Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 14, 2025
– Phase 1 monotherapy expansion study of micvotabart pelidotin (MICVO) for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients progressing well with preliminary data in second half of 2025 and first half of 2026 – Phase 1/ …